- Home
- About
- 🤖 AskAnzal AI Advisor
- 📅 Book a Call
- Your Account
- My AskAnzal Account
Over 2,000 real rulings — analysed for what they mean to your team. Published every day.
Showing 1914 cases
Complaint challenged a Blenrep website claim (“generally well tolerated and manageable safety profile”) as misleading/unqualified. Panel found the claim sufficiently supported and…
A UK health professional complained about Janssen’s HCP website. The Panel found some prescribing information was out-of-date, one graph exaggerated differences, and…
A GP complained that he continued to receive promotional emails after opting out. A third-party agency failed to remove his details, and…
A Financial Times article triggered a Director complaint about Lilly’s 40over40 ED campaign. TV ad was not in breach, but website/leaflet treatment…
AstraZeneca challenged Trinity-Chiesi’s Fostair cost comparison chart as incomplete and misleading. The Panel found the chart acceptable in context and ruled no…
A pharmacist challenged claims that Versatis was comparable to pregabalin (and possibly gabapentin) and had fewer side-effects/interactions. The Panel found interim data…
A GP received an unsolicited promotional email about MacroBid via an agency. The Panel and Appeal Board found no evidence of prior,…
AstraZeneca self-reported an uncertified promotional email about Crestor sent to a dispensing practice. The email lacked prescribing information and included misleading, exaggerated…
Two anonymous hospital HCPs alleged an AstraZeneca rep initiated discussion of unpublished/out-of-licence JUPITER (Crestor) data. Panel had concerns about internal briefings but…
A Lipitor mailer compared LDL-C lowering across statins but then presented a table implying only Lipitor/rosuvastatin/ezetimibe combos had outcomes trials. Panel ruled…
GSK and Roche withdrew Bonviva ‘Building Bones’ materials after an undertaking, but Pulse republished the old ad. Panel ruled breach of Clause…
MSD voluntarily admitted a withdrawn Cozaar (losartan) banner reappeared in MIMS Monthly Update due to publisher error. Panel ruled breach of Clause…
Complaint alleged Roche press release drove disguised promotion/off-label advertising of MabThera in early RA via newspapers/TV. Panel found UK press release factual,…
A competitor complaint about an Effentora “Titration Guidelines” booklet. Panel found a front-cover time-to-relief graphic misleading and tablet-placement images inconsistent with the…
Anonymous complaint about Taxotere reps demanding usage data and mishandling named patient AE info. Panel found one incident of forwarding named patient…
Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases — ask about precedents, clauses, and how they apply to your situation.
One real case. One key lesson. Every week — free.